ライフサイエンスコーパス: disease management

1 ences in etiology that have implications for disease management.

2 ogical processes is imperative for effective disease management.

3 towards personalized medicine and infectious disease management.

4 discuss the significance of new findings for disease management.

5 suppression and serve as biomarkers for CHB disease management.

6 rd may contribute to patient harm and impair disease management.

7 specialist care are paramount in optimizing disease management.

8 ell model, with substantial implications for disease management.

9 pathways as novel therapeutic approaches for disease management.

10 rapy, which have negative effects on primary disease management.

11 to resources and interventions essential for disease management.

12 mpact of pathogen diversity is important for disease management.

13 tial heterogeneity needs to be considered in disease management.

14 biodiversity, and has applied potential for disease management.

15 behavioral subgroups may also be relevant to disease management.

16 seful for resource poor countries for better disease management.

17 ability to transmit parasites would improve disease management.

18 glaucoma surgery (Trabectome) in 2 eyes for disease management.

19 arly-stage Alzheimer's disease diagnosis and disease management.

20 es may allow pathogenetic studies to improve disease management.

21 atments of CLL, and, possibly, for optimized disease management.

22 rdiovascular-related lifestyle behaviors and disease management.

23 lt challenges in medicine and a key facet of disease management.

24 shed case series provide limited guidance on disease management.

25 ive airway diseases and provide guidance for disease management.

26 recognition and evaluation of the effects of disease management.

27 articles hold the potential to revolutionize disease management.

28 y yield a useful therapeutic agent for heart disease management.

29 kers that can potentially be used to improve disease management.

30 resistance may be of grave consequences for disease management.

31 ations and may facilitate decision-making in disease management.

32 ures and suggest novel strategies to improve disease management.

33 kemia (CLL) and have direct implications for disease management.

34 h needed for more personalized treatment and disease management.

35 cal trial results, and current guidelines on disease management.

36 rculating tumor cells in cancer research and disease management.

37 improving care transitions, monitoring, and disease management.

38 erium responsible for an outbreak can aid in disease management.

39 of familial Mediterranean fever and Behcet's disease management.

40 , is relevant to sustainable development and disease management.

41 myeloid leukemia (AML) remain a challenge in disease management.

42 eatic tumorigenesis, cancer progression, and disease management.

43 eractivity that are useful for diagnosis and disease management.

44 ce, with important implications for targeted disease management.

45 s technology used for patient monitoring and disease management.

46 ion and trust in the nurse's role in chronic disease management.

47 t may guide the development of new drugs for disease management.

48 risk and possible beneficial effects on crop disease management.

49 to improve its use are essential for optimal disease management.

50 e to therapy, which are important aspects of disease management.

51 a significant challenge for diagnostics and disease management.

52 ents and is a cost-effective strategy in CMV disease management.

53 ction of OA pathology is needed for improved disease management.

54 D, targeted specific therapies could improve disease management.

55 prognostic biomarkers are needed for optimal disease management.

56 al health in older adults for cardiovascular disease management.

57 nd their relevance for future prevention and disease management.

58 ies and specificities necessary to influence disease management.

59 Palliative care is part of Parkinson disease management.

60 cccDNA, and assist new drug development and disease management.

61 ng of CD4 cells has remained prime focus for disease management.

62 r this transition, which further complicates disease management.

63 Registry to Evaluate Early And Long-term PAH Disease Management.

64 ell as controlled and descriptive studies of disease management.

65 tment modality, rather than on collaborative disease management.

66 that urgently necessitates a breakthrough in disease management.

67 from cccDNA and assist drug development and disease management.

68 nd drug-resistance is essential to effective disease management.

69 osis offers a promising alternative for rare-disease management.

70 d for the assessment of lung function during disease management.

71 delivering early and accurate diagnosis for disease management.

72 d ecological questions with implications for disease management.

73 itate targeting of GAS virulence factors for disease management.

74 targeted improved primary care and comorbid disease management.

75 e use of biologics and less costly long-term disease management.

76 y amyloid self-assembly events for potential disease management.

77 de valuable biochemical insights and improve disease management.

78 rial and viral infections as well as chronic disease management.

79 itically ill patients, and effective chronic disease management.

80 n essential component of integrated pest and diseases management.

81 ality for preventive care, 71.1% for chronic disease management, 65.5% for maternity care, and 80.8%

82 balancing available biologic, environmental, disease management, access to care, and socioeconomic an

83 Biologic, environmental, disease management, access, and socioeconomic hardship v

84 arly every measured biologic, environmental, disease management, access, and socioeconomic hardship v

85 Contemporary models of chronic disease management across a variety of countries point t

86 mechanisms may ensure improved prognosis and disease management against fungal infections.

87 rvice-based interventions for cardiovascular disease management also have shown benefits with respect

88 ed the use of mobile technologies to improve disease management and 26 trials investigated their use

89 ed clinical trials have clarified aspects of disease management and a disease-modifying therapeutic d

90 tion differentiation is a critical aspect of disease management and an active research area.

91 e clinical implications for early diagnosis, disease management and care planning and theoretical imp

92 ression of Parkinson's disease could improve disease management and clinical trial design.

93 responses, resulting in accurate and prompt disease management and control.

94 chanisms of evolution is important for virus disease management and controlling the emergence of new

95 Such information is important for future disease management and cost savings.

96 hese results carry implications for wildlife disease management and highlight areas for future work,

97 xamples where these principles have enhanced disease management and illustrate how they can be furthe

98 Goals of care are moving toward chronic disease management and improved long-term health.

99 isms involved with schizophrenia may improve disease management and may identify new drug targets.

100 dge of disease pathogenesis, improvements in disease management and new medical therapies that are av

101 e include systematic implementation of liver disease management and new treatment in HIV-infected pop

102 messaging into clinical practice can improve disease management and patient education.

103 k for readmission is a key step in improving disease management and patient outcome.

104 eting IDTCs would be crucial for sustainable disease management and prevention of acquired drug resis

105 early diagnosis is associated with effective disease management and reduction in HIV transmission amo

106 method can be used to standardize aneurysmal disease management and sets the foundation for complex g

107 therapy planning have been transformative in disease management and suggest potentially beneficial ap

108 ary cells will likely play a greater role in disease management and therapeutic development.

109 aster on-site diagnosis would infer improved disease management and treatment decisions.

110 fully elucidated, putting limits to current disease management and treatment.

111 ify true disease stage, spuriously informing disease management and ultimately increasing the risk of

112 ol and that biocontrol research might inform disease management and vice versa.

113 ease, (3) defining disease modification, (4) disease management, and (5) implementation research.

114 ultidisciplinary approach to thoracic aortic disease management, and a standardized protocol for ATAA

115 The addition of biologic, environmental, disease management, and access variables resulted in 80%

116 ith the chance of early intervention, better disease management, and efficient allocation of healthca

117 well-being, being better informed, improved disease management, and feeling confident in the relatio

118 herapeutic intervention, assisted subsequent disease management, and finally, 4 - information gained

119 hortens their "diagnostic odyssey," improves disease management, and fosters genetic counseling with

120 follow-up clinic, outpatient rehabilitation, disease management, and ICU diaries.

121 tightly managed system of care coordination, disease management, and preventive services provided by

122 tory cardiovascular disease activity, assist disease management, and serve as an imaging biomarker fo

123 wards better patient compliance and improved disease management, and thereby enhanced patient quality

124 icant limitations on adolescents' self-care, disease management, and transition to adult care.

125 treatment development; treatment evaluation; disease management; and health services research.

126 idemiology enabled development of integrated disease management approaches that rely heavily on diver

127 opment of novel therapeutic intervention and disease management approaches.

128 Implications of these findings for disease management are discussed.

129 of biomarkers and therapeutics for effective disease management are limited.

130 New approaches to pest and disease management are needed that take into account the

131 cidation of PARP-1 function into advances in disease management are reviewed.

132 A Disease Management Area (DMA) approach, as developed in

133 Most patients saw chronic disease management as a medicalised approach and the nur

134 progression will provide important tools for disease management, as well as for identifying the under

135 is a critical component of acute and chronic disease management, as well as health and wellness acros

136 ng methods and advanced analytics to improve disease management at an individual patient level or for

137 Their identification not only affects disease management but also may uncover key mechanisms o

138 medicine offers great potential benefits for disease management but requires continuous monitoring of

139 ibition of BCR-ABL kinase has revolutionized disease management, but fails to eradicate leukaemic ste

140 ditional epidemiology can be used to improve disease management, but it requires good prior knowledge

141 bably an important contributor to suboptimal disease management, but methodological challenges have l

142 lectronic health records (EHRs) with chronic disease management capabilities support small-practice r

143 Disease management clinics, nurse home visits (NHVs), an

144 to the Medicare program in fees paid to the disease-management companies ($400 million), with no dem

145 ay be in response to large-scale or emerging disease management concerns or in addressing complex iss

146 The evidential basis for disease management decision making is provided by data r

147 ecological and epidemiological data may aid disease management decision-making by providing a framew

148 e dispersal scales to assist in making plant disease management decisions, such as the timely applica

149 ture therapeutic options when making current disease management decisions.

150 one symptom but worsen another, which makes disease management difficult.

151 esenting time available to devote to chronic disease management during patient encounters) and diabet

152 pite significant progress in diagnostics and disease management during the past decades, human immuno

153 nhibition have shown a significant impact on disease management, emphasizing the importance of the ac

154 ing framework has been suggested for chronic disease management especially where multiple treatment o

155 ent state-of-the-art diagnostic criteria and disease management for adult and pediatric EoE.

156 e diabetes management and in general chronic disease management for billions of patients.

157 tiveness and harms of pharmacist-led chronic disease management for community-dwelling adults.

158 The current disease management for TSWV is based mainly on breeding

159 , patient self-management, surveillance, and disease management from the moment of first diagnosis to

160 management group than the moderate-intensity disease management group (odds ratio [OR], 1.43 [95% CI,

161 d higher abstinence among the high-intensity disease management group than the moderate-intensity dis

162 5% CI, 1.00 to 2.03]) and among the combined disease management groups than the pharmacotherapy-alone

163 Two trials of disease management had low risk of bias; in one, antiret

164 in our understanding of pathogen biology and disease management has been the research capacity and co

165 Disease management has proven difficult and there are no

166 Peer support models for chronic disease management have been successfully applied for ot

167 um, although a critical component of chronic disease management, have not been studied.

168 these patients has important diagnostic and disease management implications.

169 ns is essential to strategic and sustainable disease management in agricultural systems.

170 We looked at growth, anthropometry and disease management in children with dual diagnosis (T1DM

171 acerbations will strike and may thus improve disease management in critical care medicine.

172 ndly strategies is required to advance virus disease management in diverse agricultural cropping syst

173 e dermatology profession needs to understand disease management in dollar terms to advocate on behalf

174 ght critical issues for immunotherapy and HD disease management in general.

175 rom transfusions that represent the basis of disease management in most patients with severe thalassa

176 ing research to improve stress tolerance and disease management in production systems.

177 diagnostics that will be transformative for disease management in resource-limited settings by enabl

178 While traditional approaches for disease management in the era of modern medicine have sa

179 t practical applications in animal and human disease management in the face of highly prevalent paras

180 overall viral fitness, with implications for disease management in the future.

181 teractions may be particularly important for disease management in the tropics, a region with both hi

182 nd monitoring CKD for the purpose of chronic disease management (including testing and monitoring pat

183 phy which may have clinical implications for disease management, including prosthetic restoration str

184 of co-infections can be useful in designing disease management interventions.

185 Chronic disease management is an increasingly important aspect o

186 s of treatment suggest that higher-intensity disease management is associated with increased abstinen

187 role of pulmonary rehabilitation in chronic disease management is highlighted.

188 n Americans (eg, heart failure medications), disease management is less effective among African Ameri

189 Disease management is multifaceted and multidisciplinary

190 e in patients willing to contribute to their disease management, limited data exist on the clinical a

191 tion is advantageous in the absence of other disease management methods, especially under conditions

192 In the future, disease management might rely on severity scores that in

193 A chronic disease management model is effective for treating tobac

194 latform to examine OSA outcomes in a chronic disease management model.

195 and Medicaid Services to test the commercial disease-management model in the Medicare fee-for-service

196 processes and outcomes of effective chronic disease management models and the nursing contributions

197 ngland and Wales ensuring a range of chronic disease management models.

198 ommunity-based support (n = 20), and chronic disease management (n = 3).

199 Registry to Evaluate Early And Long-term PAH Disease Management (N=3515), 734 patients who met SERAPH

200 up to 2 counseling calls (moderate-intensity disease management) (n = 249), or pharmacotherapy supple

201 ith up to 6 counseling calls (high-intensity disease management) (n = 251).

202 Ecological disease management needs to target diverse production si

203 essive array of therapies aimed at improving disease management, no means for a practical "cure" exis

204 d have practical applications for infectious disease management of endangered wildlife species.

205 Infectious disease management of Staphylococcus aureus bacteremia (

206 stribution of primary and hepatic metastatic disease, management of chemotherapy, surgery, the sequen

207 der adults for HIV, diagnosis of concomitant diseases, management of multiple comorbid medical illnes

208 t reported 25 outcomes regarding appropriate disease management, of which 11 showed statistically sig

209 host resistance is considered a sustainable disease management option but may often be incomplete or

210 sed oncologic risk when deciding among their disease management options.

211 gement need to be considered alongside other disease management options.

212 l examination of the funnel plots for either disease management or health behaviours.

213 or or manage pathogen movement for proactive disease management or quarantine measures.

214 genetics, cultural or social differences in disease management, or low power and statistical chance.

215 rom 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data.

216 With respect to disease management, partial compliance can undermine att

217 s to aid patient selection, establishment of disease management pathways and collaboration with speci

218 gistered nurses play a large role in chronic disease management, patient education, medication manage

219 Registry-to-Evaluate-Early-And-Long-term PAH disease management)-pediatric criteria, and 32 (15%) acc

220 inic might allow expansion of PET's roles in disease management, perhaps to earlier stages of disease

221 52) of the patients were enrolled into an HF disease management plan to reduce early readmission.

222 -risk patients who benefited most from an HF disease management plan.

223 developed here provides a flexible tool for disease management planners which translates modeling re

224 tronic medical records to develop innovative disease management plans that will track asthma over tim

225 tronic medical records to develop innovative disease management plans that will track asthma over tim

226 In some high-income countries use of chronic disease management principles and primary care-based col

227 ive cohort study of patients attending an HF disease management program.

228 ative person-centred approach, tailoring the disease management programme to address the patient's il

229 ad and impact of disease and may help inform disease management programmes as well as the conservatio

230 We believe that disease management programmes can be helpful in providin

231 Trials investigating efficacy of disease management programs (DMP) in heart failure repor

232 Although disease management programs for patients hospitalized wi

233 pitals that used postdischarge heart failure disease management programs had lower relative readmissi

234 Disease management programs have shown promise but lack

235 th care interventions, such as heart failure disease management programs, are under increasing pressu

236 The eight commercial disease-management programs did not reduce hospital admi

237 In this large study, commercial disease-management programs using nurse-based call cente

238 ed to inform population health approaches to disease management: proportion of cases followed and pro

239 Registry to Evaluate Early And Long-term PAH Disease Management, providing an opportunity to compare

240 n, disease prevention, diagnosis, treatment, disease management, rehabilitation, and palliative care

241 To-date, there is no effective cure and disease management relies on early detection and removal

242 re patterns can help focus crop breeding and disease management research.

243 Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) as a means to compare observ

244 nd Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) equation, REVEAL risk score,

245 Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess pred

246 Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a longitudinal registry of

247 Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

248 Registry to Evaluate Early and Long-Term PAH Disease Management) risk score calculator (REVEAL 2.0) i

249 Registry to Evaluate Early and Long-Term PAH Disease Management score, the Pulmonary Hypertension Con

250 city mechanisms, which may help inform novel disease management strategies against fusarial pathogens

251 e most recent studies on newer therapeutics, disease management strategies and treatment recommendati

252 p received all standard medical, device, and disease management strategies available.

253 reat area of interest is early diagnosis and disease management strategies for cardiovascular disease

254 stem, but they also point to new targets for disease management strategies in a changing climate.

255 Integrated disease management strategies often exploit cultivar res

256 Effective disease management strategies to prevent catastrophic cr

257 rch and global implementation of generalized disease management strategies to reduce economic and env

258 cations for and effects on plant disease and disease management strategies, are summarized.

259 We also review disease management strategies, including promising new t

260 disease spread and determine more effective disease management strategies.

261 an optimisation in developing cost-effective disease management strategies.

262 w avenues to improve therapeutic options and disease management strategies.

263 , and have been useful to develop successful disease management strategies.

264 rovide more efficient clinical diagnosis and disease management strategies.

265 uld inform which individuals require adjunct disease management strategies.

266 tudies on the development of effective plant disease management strategies.

267 cise subgroup classifications, and effective disease management strategies; all informed by immediate

268 nce of a thorough, independent evaluation of disease-management strategies before their adoption.

269 , and managed to inform the design of better disease-management strategies.

270 Here, we show that this seemingly successful disease management strategy can fail with devastating co

271 ncer, active surveillance is the recommended disease management strategy.

272 t application of anti-virulence therapy as a disease-management strategy.

273 nts to functioning in the context of chronic disease management, summarize current transition practic

274 n in suspected patient samples to facilitate disease management, surveillance, and control.

275 A closed-loop disease management system is an ideal solution for such

276 cally influenced production of cucurbits and disease management systems at multiple scales.

277 nformation leading to changes in therapy and disease management that could prevent or delay the onset

278 mized study of eight commercial programs for disease management that used nurse-based call centers.

279 For safe and effective closed-loop disease management, the cost, size, longevity, warm-up t

280 d severity to advancements that will improve disease management throughout the lifespan.

281 nalized screening, surveillance, and chronic disease management to help manage chronic conditions, re

282 and new care models, we can redesign chronic disease management to include fewer in-person visits whe

283 sive continuous glucose monitors for chronic disease management to non-invasive sweat electrolyte sen

284 nwide data suggest a need for better thyroid disease management to reduce neonatal morbidity.

285 stage is crucial for effective treatment and disease management to slow disease progression and preve

286 al contribution of quality of cardiovascular disease management to this increased risk.

287 d payment model with a longitudinal focus on disease management (to reduce adverse clinical outcomes

288 Current disease management tools, such as the Integrated Managem

289 nly nano MgO was effective in bacterial spot disease management under field conditions.

290 reported outcomes of pharmacist-led chronic disease management versus a comparator for community-dwe

291 Disease management was assessed by the self-reported his

292 Conclusion: Pharmacist-led chronic disease management was associated with effects similar t

293 Anorexia could be exploited to improve disease management; we propose an interdisciplinary appr

294 ent is part of public health surveillance or disease management were excluded.

295 nts' preferences and expectations of chronic disease management were framed by a strongly biomedical

296 Four clinically important questions in bone disease management were identified, and recommendations,

297 Perceptions of nurse-led chronic disease management were often shaped by what was previou

298 o improvements in prediction, prevention and disease management, which may ultimately reduce the disp

299 clinical development of targeted agents, and disease management with conventional chemotherapy.

300 nary and epidemiological dynamics and inform disease management, yet very little empirical work has a